AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca Pharma India reported its financial results for Q2 FY25, showing a notable revenue increase. Revenue from ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

RSV symptoms include cough, fever, running nose, irritability, reduced activity, and pauses in breathing. Severe cases can ...

AstraZeneca Pharma tumbled 5.12% to Rs 6,768 after the pharmaceutical firm's net profit declined 26.62% to Rs 38.43 crore in Q2 FY25 as compared with Rs 52.37 crore posted in Q2 FY24.

The pneumococcal conjugate vaccine—known as PCV—prevents around 30 percent of pneumonia, the most common cause of childhood ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

The Commonwealth of Dominica will bestow its highest national award, the Dominica Award of Honour, upon Prime Minister ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...